Skip to main content

Month: March 2026

EDAP to Present at Oppenheimer 36th Annual Healthcare MedTech & Services Conference

EDAP to Present at Oppenheimer 36th Annual Healthcare MedTech & Services Conference Company to Present and Host 1×1 Investor Meetings on Wednesday, March 18th, 2026 AUSTIN, Texas, March 10, 2026 — EDAP TMS SA (Nasdaq: EDAP) (“the Company”), the global leader in robotic energy-based therapies, today announced that Ryan Rhodes, Chief Executive Officer, is scheduled to present and, together with Ken Mobeck, Chief Financial Officer, will host 1×1 investor meetings at the upcoming Oppenheimer 36th Annual Healthcare MedTech & Services Conference. Date: Wednesday, March 18th Time: 12:00-12:30 PM ET Format: Virtual Presentation and 1×1 investor meetings Webcast:https://event.summitcast.com/view/2MZVg3DCx8a3zxe3mMMekq/6YGp8gAgsNuJhACXjn75JB The live and archived webcast of the presentation can be accessed in the...

Continue reading

Kane Biotech Expands U.S. Commercial Footprint with Strategic Distribution Partnership

Kane also signs U.S.-based contract sales agents WINNIPEG, Manitoba, March 10, 2026 (GLOBE NEWSWIRE) — Kane Biotech Inc. (Kane or the Company), transforming wound care with three FDA 510(k) cleared and two Health Canada approved formats, is pleased to announce two significant expansions to its U.S. commercialization strategy as it prepares for nationwide growth of its advanced wound care portfolio, including the revyve® Antimicrobial Wound Gel. These strategic steps include the signing of a federally aligned distribution partnership to support entry into the U.S. Veterans Affairs (VA) market, the U.S. Department of Defense (DOD), and U.S. Indian Health Services (IHS) and the signing of multiple independent sales representative agreements. U.S. FDA 510(k) cleared and Health Canada approved revyve Antimicrobial Wound Gel and revyve...

Continue reading

WestKam Gold Corp. Announces Name Change to Big Bear Gold Corp. and New Symbol “BEAR”

Vancouver, BC, Canada, March 10, 2026 (GLOBE NEWSWIRE) — WestKam Gold Corp. (TSXV:WKG) (the “Company”) is pleased to announce that it will be changing its name to “Big Bear Gold Corp.” effective Thursday, March 12, 2026. The Company’s common shares will commence trading on the TSX Venture Exchange under the new name “Big Bear Gold Corp.” at the opening of trading on March 12, 2026, under the new trading symbol “BEAR”.  The Company’s new CUSIP number is 088936109 and its new ISIN number is CA0889361097. There is no change in the share capital of the Company and no action will be required by existing shareholders with respect to the name change.  Certificates representing common shares of WestKam Gold Corp. will not be affected by the name change and will not need to be exchanged.  The Company encourages any shareholders with any...

Continue reading

Willis Lease Finance Corporation Reports Record 2025 Financial Results

Delivers Record Pre-Tax Income of $160.6 Million and Record Revenue of $730.2 Million COCONUT CREEK, Fla., March 10, 2026 (GLOBE NEWSWIRE) — Willis Lease Finance Corporation (NASDAQ: WLFC) (“WLFC” or the “Company”), the leading lessor of commercial aircraft engines and global provider of aviation services, today announced its financial results for the year ended December 31, 2025. 2025 Highlights (All metrics compared to 2024, except if noted)Record high annual total revenue of $730.2 million, an increase of 28.3% Record high pre-tax income of $160.6 million, an increase of 5.2% Record high lease rent revenue of $291.6 million, an increase of 22.4% Record high maintenance reserve revenue of $232.0 million, an increase of 8.4% Record high spare parts and equipment sales of $95.5 million, an increase of 252.3% Record high gain...

Continue reading

Prelude Therapeutics Reports Full Year 2025 Financial Results and Provides Program Outlook for 2026

Received FDA clearance of Investigational New Drug application (IND) for PRT12396, mutant-selective JAK2V617F inhibitor in the first quarter of 2026 Phase 1 study of PRT12396 in patients with polycythemia vera and myelofibrosis anticipated to initiate by Q2 2026 Preclinical development and IND enabling studies for PRT13722, highly-selective oral KAT6A degrader underway, and the Company intends to file the IND for PRT13722 in mid-2026 with Phase 1 study initiation anticipated in the 2nd half of 2026 Current cash runway expected into second quarter of 2027 with $106 million in cash, cash equivalents, restricted cash and marketable securities as of December 31, 2025  WILMINGTON, Del., March 10, 2026 (GLOBE NEWSWIRE) — Prelude Therapeutics Incorporated (Nasdaq: PRLD), a clinical-stage precision oncology company, today reported its...

Continue reading

Opus Genetics Announces Financial Results for Full Year 2025 and Provides Corporate Update

– Favorable early safety and initial efficacy data from BEST1 program highlighted at premier gathering of global retinal experts with additional data expected mid-year 2026 – – Reauthorization of FDA’s Rare Pediatric Disease Priority Review Voucher (PRV) program provides opportunity for Opus’ deep pipeline in rare inherited retinal diseases – – FDA Prescription Drug User Fee Act (PDUFA) date in October 2026 for Phentolamine Ophthalmic Solution 0.75% for the treatment of presbyopia – – Funding from prominent healthcare investors expected to extend cash runway into 2028 – RESEARCH TRIANGLE PARK, N.C., March 10, 2026 (GLOBE NEWSWIRE) — Opus Genetics, Inc. (Nasdaq: IRD) (the “Company” or “Opus Genetics”), a clinical-stage biopharmaceutical company developing gene therapies to restore...

Continue reading

ABM Reports Fiscal First Quarter 2026 Results and Reaffirms Fiscal 2026 Outlook

Revenue was $2.2 billion, an increase of 6.1% over the prior year, including organic growth of 5.5% Net income totaled $38.8 million, or $0.64 per diluted share, as compared to $43.6 million or $0.69 in the prior year Adjusted net income was $50.4 million, or $0.83 per diluted share, versus $55.3 million, or $0.87, in the prior year Adjusted EBITDA was $117.8 million, versus $120.6 million last year Operating cash flow was $62.0 million and free cash flow totaled $48.9 million, both up significantly over the prior year The Company repurchased $91.1 million of common stock during the quarter at an average price of $44.13 per shareNEW YORK, March 10, 2026 (GLOBE NEWSWIRE) — ABM (NYSE: ABM), a leading provider of facility, engineering and infrastructure solutions, today announced financial results for its fiscal first quarter...

Continue reading

NIO Inc. Reports Unaudited Fourth Quarter and Full Year 2025 Financial Results

Quarterly Adjusted Profit From Operations (non-GAAP) Reached RMB1,251.3 Million (US$178.9 Million)i Quarterly Total Revenues Reached RMB34,650.2 Million (US$4,954.9 Million)iQuarterly Vehicle Deliveries Were 124,807 Units Full Year Total Revenues Reached RMB87,487.5 Million (US$12,510.5 Million) Full Year Vehicle Deliveries Were 326,028 Units SHANGHAI, China, March 10, 2026 (GLOBE NEWSWIRE) — NIO Inc. (NYSE: NIO; HKEX: 9866; SGX: NIO) (“NIO” or the “Company”), a pioneer and a leading company in the global smart electric vehicle market, today announced its unaudited financial results for the fourth quarter and full year ended December 31, 2025. Operating Highlights for the Fourth Quarter and Full Year of 2025Vehicle deliveries were 124,807 in the fourth quarter of 2025, representing an increase of 71.7% from the fourth quarter...

Continue reading

Reliance, Inc. Subsidiary AMI Metals, Inc. Awarded Significant Government Infrastructure and Defense Projects

Multi-year contract with U.S. Department of Homeland Security (“DHS”) for up to $2.24 billion to provide steel and steel logistics support services Five-year IDIQ contract for up to $654 million to supply aluminum plate across multiple Lockheed Martin Corporation (“Lockheed Martin”) defense platformsPHOENIX, March 10, 2026 (GLOBE NEWSWIRE) — Reliance, Inc. (NYSE: RS) announced today that its wholly-owned subsidiary, AMI Metals, Inc. (“AMI”) has been awarded two significant contracts for United States government infrastructure and defense projects, reinforcing the Company’s position as a trusted partner in the aerospace and defense market.AMI was awarded a multi-year contract by the United States DHS to provide steel and steel logistics support services for the construction of the border wall for a total maximum estimated value...

Continue reading

BioNTech Announces Fourth Quarter and Full Year 2025 Financial Results and Corporate Update

BioNTech on track for a catalyst-rich year with six late-stage data readouts expected across immunomodulators, antibody-drug conjugates and mRNA cancer immunotherapiesIncreased focus on PD-L11/VEGF-A bispecific immunomodulator pumitamig with eight global Phase 3 clinical trials planned to be ongoing for year-end in collaboration with Bristol Myers SquibbFull year 2025 revenues of €2.9 billion2, net loss of €1.1 billion (adjusted3 net loss of €0.1 billion) and diluted loss per share of €4.70 ($5.314) (adjusted3 diluted loss per share of €0.48 ($0.554))Strong financial position continues to de-risk execution with cash, cash equivalents and security investments of €17.2 billion5 Expect 2026 total revenues of €2.0 billion to €2.3 billion, adjusted3 R&D expenses between €2.2-2.5 billion and adjusted3 SG&A expenses7 between...

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.